Drug Trial Radar · NCT03362684
PETACC-8 miR-31-3p and miR-31-5p Ancillary Study
Last checked: Nov 20, 2026Latest source record: Dec 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,808
Actual
Start
Nov 2005
Primary completion
Nov 2009
Study completion Jun 30, 2016
Sponsor
- Lead sponsor
- IntegraGen SAIndustry
- Sponsor type
- Industry
- Collaborators
- Federation Francophone de Cancerologie Digestive; Exystat
- First posted
- Dec 5, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective-retrospective study to determine if the expression of the miRNA's miR-31-3p and miR-31-5p are prognostic of patient outcomes or predictive of the benefit from anti-EGFR therapy in stage III Colon Cancer. The present study will utilize FFPE tumor samples collected from patients enrolled in the PETACC-8 study conducted by the Fédération Francophone de Cancérologie Digestive (FFCD). This phase 3 clinical trial prospectively randomized fully resected stage III colon cancer patients to receive adjuvant treatment with either FOLFOX-4 plus cetuximab or FLOFOX-4 alone.
Conditions
- Colorectal Cancer
Interventions
CetuximabDrug
Cetuximab every 2 weeks
FOLFOXDrug
FOLFOX-4 every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Free Survival (DFS)Time frame: From date of randomization until the date of first documented any signs or symptoms cancer relapse or date of death, whichever came first, assessed up to 7 years
- Prognostic and predictive value of miR-31-3p expression on Disease Free Survival (DFS)Time frame: From date of randomization until the date of first documented any signs or symptoms cancer relapse or date of death, whichever came first, assessed up to 7 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.